TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: FAAH Availability in Psychiatric Disorders: A PET Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18 and 65 years, inclusive~* Good physical health as determined by history, physical and laboratory examinations, ECG, and vital signs~PTSD Inclusion Criteria:~* Diagnosis of Post-Traumatic Stress Disorder~AUD Inclusion Criteria:~* Diagnosis of Alcohol Use Disorder~Psychosis Inclusion Criteria:~* Diagnosis of psychotic disorder such as Schizophrenia, Schizoaffective disorder~Exclusion Criteria:~* Presence of ferromagnetic metal in the body or heart pacemaker~* Women with a positive pregnancy test or women who are lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- [11C]MK-3168 PET Scan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III or IV epithelial or germ cell ovarian cancer that is unlikely to respond to existing therapy and for which no curative therapy exists~* Measurable disease by CT scan or MRI~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/mL~* No renal insufficiency~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No history of congestive heart failure~* No other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease (e.g., chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception for 4 weeks before, during, and for 4 weeks after study participation~* No active infection~* No concurrent serious systemic disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* Concurrent corticosteroids allowed (e.g., dexamethasone or methylprednisone)~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplaston therapy~* No other concurrent antineoplastic agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ga-68-PSMA-11 in Men With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to tolerate PET/CT imaging and one or more of the following:~* Patients with newly diagnosed prostate cancer with primary staging classified at high/intermediate risk per NCCN guidelines OR~* Biochemical Recurrence: Patients with rising PSA after definitive therapy with prostatectomy or radiation therapy or other local therapies~Exclusion Criteria:~* Claustrophobia or any other condition that would preclude PET/CT imaging.~* Any constellation of medical conditions that indicate expectancy of less than one year

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ga-68-PSMA-11 PET/CT (Type: EXPERIMENTAL): Administration of Ga-68-PSMA-11 and acquisition of PET/CT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Colorectal Cancer (CRC) Cetuximab Elderly Frail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed metastatic colorectal cancer~* Measurable disease according to RECIST V1.1~* Histological local review and analysis of KRAS~* Age ≥ 80 or ≥ 70 in combination with functional restrictions defined as limitation in at least 2 of 8 IADL~* WHO performance status 0, 1 or 2~* Adequate bone marrow reserves, hepatic function \& renal function~* Normal 12 lead ECG without clinically significant abnormalities~* Written informed consent before randomization according to ICH/EU GCP, and local, national and international regulations~Exclusion Criteria:~* Prior systemic chemotherapy for metastatic disease~* Previous exposure to EGFR or VEGF/VEGFR targeted therapy~* Patients may have received chemotherapy in the adjuvant or neoadjuvant setting (CRC). The treatment-free interval should be 6 months or more from the end of (neo-)adjuvant therapy~* Previous radiotherapy, either in the adjuvant setting or for the treatment of bone metastases, is allowed provided that the measurable lesions are outside the radiation fields~* Persistence of clinically relevant treatment-related toxicities from previous chemotherapy and/or radiotherapy (adjuvant or neo-adjuvant setting)~* Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of treatment or concomitantly with this trial~* Known alcohol or drug abuse~* Clinically significant cardiovascular disease~* Evidence of uncontrolled medical comorbidities despite adequate treatment~* Patients who have suffered a cerebrovascular accident or transient ischemic attack within the past 12 months~* History, within the past 5 years, of malignancies other than CRC~* Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and followup schedule

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5-fluorouracil/leucovorin plus cetuximab (Type: EXPERIMENTAL): None
- 5-fluorouracil/leucovorin alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable or definite Amyotrophic Lateral Sclerosis (ALS) per El Escorial criteria~* Between ages of 18 and 80 yrs old~Exclusion Criteria:~* Inability to clear secretions from the airway~* Life expectancy \< 6 months from a comorbid condition~* Dementia sufficient to impair ability to use NIV, perform respiratory muscle pressure testing (PFTs), or complete Health-related Quality of Life (HRQOL) instruments~* Inability to follow up at the ALS Center on a regular basis~* Previously diagnosed obstructive Sleep Apnea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard NIV (Type: ACTIVE_COMPARATOR): Noninvasive ventilation (NIV) will be initiated and managed as per current standard of practice guided by the American Academy of Neurology (AAN) Practice Parameters (updated in 2009), in all subjects with amyotrophic lateral sclerosis (ALS) and a forced vital capacity of \<50% predicted. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months, but will not influence management of the NIV.
- Sleep study titrated NIV (Type: EXPERIMENTAL): ALS subjects in this arm, who are offered NIV for Forced Vital Capacity (FVC) \<50% as per AAN Practice Parameters, will have their initial level of NIV determined polysomnographically. They will be followed with sleep studies at 1 month, 3 months and 6 months to reassess NIV efficacy and NIV will be adjusted as necessary to optimize parameters of oxygenation and ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix~  * Stage IB2, IIA, IIB, IIIB, or IVA disease~    * Stage IIA tumors must be \> 4 cm~ * Primary, untreated disease~* Negative, non-suspicious para-aortic nodes by lymphangiogram, CT scan, MRI, or lymphadenectomy~* Must have been adequately clinically staged~* Suitable for treatment with radical intent using concurrent chemotherapy and pelvic radiotherapy~* No disease involvement of the lower third of the vagina regardless of stage (all stage IIIA, IIIB and IVA with lower one-third involvement)~* No carcinoma of the cervical stump~* Performance status - GOG 0-3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* SGOT ≤ 3 times ULN~* Alkaline phosphatase ≤ 3 times ULN~* Creatinine ≤ ULN or calculated creatinine clearance ≥ 60mL/min~* No New York Heart Association class III-IV heart failure~* No history of myocardial infarction~* No unstable angina~* No uncontrolled hypertension~* No pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No septicemia or severe infection~* No other invasive malignancy within the past 5 years except nonmelanoma skin cancer~* No prior hysterectomy or planned hysterectomy as part of initial cervix cancer therapy~* No prior coronary artery bypass surgery~* No prior cancer therapy that would preclude study treatment~* No concurrent angina medication~* No concurrent intensity-modulated radiotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (cisplatin) (Type: ACTIVE_COMPARATOR): Patients receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6).
- Arm II (cisplatin, tirapazamine) (Type: EXPERIMENTAL): Patients receive tirapazamine IV over 2 hours on days 1, 8, 10, 12, 15, 22, 24, 26, and 29 and cisplatin IV over 1 hour on days 1, 15, and 29.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Superficial Cervical Plexus Block for Pacemaker Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-100 years old~* Registered patients at Mayo Clinic in Florida scheduled to undergo primary insertion of pacemaker~Exclusion Criteria:~* Emergency placement of pacemaker~* Sub-pectoral placement of pacemaker~* Patients with history of chronic pain~* Patients with anatomical abnormality or disruption to the pacemaker insertion site or site of block placement~* Patients with allergy to local anesthetic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Superficial Cervical Plexus Block (Type: ACTIVE_COMPARATOR): None
- Local Infiltration (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hypogonadotropic Hypogonadism in Obese Young Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males~* Age 18-30 years inclusive will be recruited.~A total of 90 males will be recruited:-~* 30 obese males (defined as BMI ≥30 kg/m2) with HH,~* 30 obese males with normal FT concentrations and~* 30 lean males (defined as BMI \<25 kg/m2) with normal FT concentrations.~Exclusion Criteria:~* Use of androgens, clomiphene, hCG, aromatase inhibitors or over the counter health supplements which contain androgens currently or in the past 6 months~* Hematocrit \> 50%~* Congestive heart failure~* currently suffering from depression~* type 1 diabetes~* Hepatic disease (transaminase \> 3 times normal) or cirrhosis~* Renal impairment (eGFR\<30 ml/min/1.73m2)~* HIV or Hepatitis C positive status~* Participation in any other concurrent clinical trial~* currently suffering from foot ulcer, significant periodontal disease or any other chronic infectious condition

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Obese males with hypogonadism-active (Type: ACTIVE_COMPARATOR): Subjects will be randomized to receive clomiphene capsules
- Obese males with hypogonadism-placebo (Type: PLACEBO_COMPARATOR): Subjects will be randomized to receive placebo capsules
- Obese males with normal testosterone (Type: NO_INTERVENTION): comparison group
- lean males with normal testosterone (Type: NO_INTERVENTION): comparison group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Psychiatrically stable subjects with schizophrenia who have had a suboptimal response to current treatment~* Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.~* Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.~Exclusion Criteria:~* History of seizures or of a condition with risk of seizures.~* Subjects with schizophrenia that have not responded at all to current treatment.~* Pregnant or nursing females, and females of child bearing potential.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PF-02545920 (5mg) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-02545920 (15mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed SCLC with known UGT1A genotype.~* Patients who have received at least 1 prior platinum-based chemotherapy.~* Life expectancy of 3 months or more.~* Measurable disease.~Exclusion Criteria:~* Patients with UGT1A polymorphism.~* Currently receiving chemotherapy.~* Pregnant and nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab and Irinotecan (Type: EXPERIMENTAL): Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study to Assess the Early Use of Porcine Cross-linked Collagen Paste in Cryptoglandular Anorectal Fistulas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
* Inclusion Criteria:~  o Clinical diagnosis of Cryptoglandular fistula in ano.~* Exclusion Criteria:~  * Insulin dependent diabetes~ * Thyroid disease~ * Fistula secondary to Crohn's disease/Ulcerative Colitis~ * Clinical or radiological evidence of secondary tracts.~ * Complex fistula tracts on MRI scan such as Horseshoe fistula, anorectal-vaginal fistula~ * Patients refusing informed consent for admission to the study.~ * Previous fistulotomy/fistulectomy~ * Pregnancy~ * Patients unable to consent~ * Patients not suitable for MRI scan those with- Cochlear implant, Permanent pacemaker, Implanted metal work, Aneurysm clips, Claustrophobia, Metallic foreign body

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Collagen paste (Type: EXPERIMENTAL): Injection of Permacol Collagen paste into the fistula tract.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Blood Glucose Monitoring With the Non-invasive Medical Device D-Base

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of type 1 or type 2 diabetes~* HbA1c \<10%~* An understanding of and willingness to follow the protocol~* Signed informed consent~Exclusion Criteria:~* Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment~* Hypoglycemia unawareness~* Have extensive skin changes/diseases at the proposed measurement site (wrist) that could interfere with the accuracy of glucose measurements.~* Female subjects: pregnancy, lactation period, lack of a negative pregnancy test (except in case of menopause, sterilization or hysterectomy)~* Serious acute or chronic disease besides diabetes mellitus or an anamnesis which might, in the opinion of the investigator, pose a risk to the subject, e.g. seizure disorder, adrenal disorder, dialysis for renal failure, cystic fibrosis, active infection~* Severe diabetes related complications (i.e. severe macro angiopathy, severe micro angiopathy, severe neuro-, retino- or nephropathy) when unstable (defined by event or increasing symptoms in the last 6 months) or with insufficient therapy~* Any incapacity or general condition that, in the opinion of the investigator, prevents adequate compliance with the study procedures, e.g. mental or visual incapacity, tremor, language barriers, alcohol or drug misuse~* Not able to understand, write or read German~* Dependency from the sponsor or the clinical investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility